

Kinnitas:	Katrin Reimand	Osakonnajuhataja	15.02.2023
Koostas:	Anneli Aus Kaja Vaagen Piret Mihkelson	Laboriarst Vanemlaboriarst Laborispetsialist	15.02.2023
	Ees- ja perekonnanimi	Ametikoht	kuupäev

Reference values for haematology tests

Analyte Abbreviation	Age	Sex	Value	Unit	Reference		
COMPLETE BLOOD CELL COUNT 5-DIFF, B-CBC-5DIFF BLOOD SMEAR MICROSCOPY, B-SMEAR-M PANEL							
RBC B-RBC	≥18y	F	4,1–5,2	10 ¹² /L	17		
		M	4,5–5,7				
	0d – <7d	M/F	4,0–6,6		5		
	7d – <14d		3,9–6,3				
	14d – <1m		3,6–6,2				
	1m – <2m		3,0–5,4				
	2m – <3m		2,7–4,9				
	3m – <6m		3,5–5,2				
	6m – <1y		3,5–5,6				
	1y – <4y		3,9–5,0			26	
	4y – <14y		M				4,1–5,1
			F				4,0–5,0
	14y – <18y	M	4,3–5,7				
		F	4,0–5,4				
WBC B-WBC	≥18y	M/F	4,1–9,7	10 ⁹ /L	17		
	0h – <12h		9,0–30,0			8	
	12h – <24h		13,0–38,0				
	24h – <7d		9,4–34,0				
	7d – <14d		5,0–21,0				
	14d – <1m		5,0–20,0				
	1m – <6m		5,0–19,5				
	6m – <1y		6,0–17,5				
	1y – <3y		5,8–13,5		26		
	3y – <5y		4,9–11,8				
	5y – <18y		4,2–10,0				
Hb B-Hb	≥ 18y	F	121–150	g/L	17		
		M	134–170				
	0d – <7d	M/F	145–225		5		
	7d – <14d		135–215				
	14d – <1m		125–205				
	1m – <2m		100–180				
	2m – <3m		90–140				
	3m – <6m		110–147				
	6m – <1y		106–145				
	1y – <4y		100–132			26	
	4y – <14y		112–141				

Analyte Abbreviation	Age	Sex	Value	Unit	Reference			
	14y – <18y	M	129–167					
		F	112–151					
Hct B-Hct	≥18y	M	40–49	%	17			
		F	37–45					
	0d – <7d 7d – <14d 14d – <1m 1m – <2m 2m – <3m 3m – <6m 6m – <1y 1y – <4y 4y – <14y	M/F			45–67	5		
					42–66			
					39–63			
					31–55			
					28–42			
					31–45			
					31–44			
					31–39			
					34–43			
					39–50			
	14y – <18y	M	39–50		26			
		F	35–45					
Plt B-PLT	≥18y	M/F	157–372	10 ⁹ /L	17			
	0d – <18y		145–390		4			
	1y – <12y		203–431		26			
	12y – <18y		173–361					
MPV B-MPV	≥18y	M/F	9,2–12,3	fL	17			
	1y – <4y		8,3–10,7		26			
	4y – <18y		9,0–12,8					
Pct B-Pct	≥18y	M/F	0,18–0,38	%	17			
LCR B-LCR	≥18y	M/F	17,8–45,1	%	17			
PDW B-PDW	≥18y	M/F	10,1–16,2	fL	17			
IPF B-IPF	≥18y	M/F	1,3–7,0	%	17			
MCV B-MCV	≥18y	M/F	82–95	fL	17			
	0d – <7d		95–121			5		
	7d – <14d		88–126					
	14d – <1m		86–124					
	1m – <2m		85–123					
	2m – <3m		77–115					
	3m – <6m		74–98					
	6m – <1y		71–90					
	1y – <4y		74–84				26	
	4y – <14y		M					78–91
			F					77–92
	14y – <18y		M/F				80–95	
	MCH B-MCH	≥18y	M/F	28–33	pg		17	
0d – <7d		31–37		8				
7d – <2m		28–40						

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
	2m – <3m		26–34		26
	3m – <6m		25–35		
	6m – <1y		23–31		
	1y – <4y		23,5–28,2		
	4y – <14y		25,1–30,3		
	14y – <18y		25,6–32,0		
MCHC B-MCHC	≥ 18y	M/F	322–356	g/L	17
	0d – <7d		310–350		5
	7d – <1m		305–355		
	1m – <3m		310–350		
	3m – <6m		305–350		
	6m – <1y		310–350		
	1y – <18y		310–345		26
RDW-CV B-RDW-CV	≥18y	M/F	12–15	%	17
	0d – <1y		11–16		5
	1y – <14y		12–15		26
	14y – <18y		12–16		
RDW-SD B-RDW-SD	≥18y	M/F	38–48	fL	17
	1y – <14y		35–44		26
	14y – <18y		M		36–45
F		37–46			
Ret% B-Ret% Ret B-Ret #	≥ 18y	M/F	0,5–2,5	%	3
			50–100		
Neut% B-Neut% Neut B-Neut#	≥18y	M/F	42,0–71,0	%	17
	1y – <5y		18,6–68,6		26
	5y – <15y		28,9–67,9		
	15y – <18y		39,6–73,9		
	≥18y	M/F	1,9–6,7	10 ⁹ /L	17
	0h – <12h		6,0–26,0		8
	12h – <24h		6,0–28,0		
	24h – <7d		5,0–21,0		
	7d – <14d		1,5–10,0		
	14d – <1m		1,0–9,5		
	1m – <6m		1,0–9,0		
	6m – <1y		1,0–8,5		
	1y – <18y		1,5–6,8		26
	Neutrophils band form% B- Neut Band% *Appears only in B- Smear-m panel		≥ 18y		M/F
Lymph% B-Lymph% Lymph	≥18y	M/F	21,0–45,0	%	17
	1y – <5y		20,6–71,6		26
	5y – <15y		21,1–58,8		

Analyte Abbreviation	Age	Sex	Value	Unit	Reference			
B-Lymph#	15y – <18y		15,0–45,4	10 ⁹ /L	17			
	≥18y		1,3–3,1					
	0h – <24h		2,0–11,0			8		
	24h – <7d		2,0–11,5					
	7d – <1m		2,0–17,0					
	1m – <6m		2,5–16,5					
	6m – <1y		4,0–13,5					
	1y – <5y		1,9–6,3			26		
	5y – <15y		1,3–4,1					
	15y – <18y		1,3–3,4					
Mono% B-Mono% Mono B-Mono#	≥18y	M/F	4,0–11,0	%	17			
	1a – <5a		5,1–12,6		26			
	5a – <18a	M	5,1–11,5	10 ⁹ /L	17			
		F	4,3–12,1					
	≥18y	M/F	0,24–0,8			5		
	0d – <7d		0,5–1,7					
	7d – <14d		0,3–1,3					
	14d – <3m		0,5–1,8					
	3m – <6m		0,2–1,6					
	6m – <1y		0,2–1,4					
	1y – <5y		0,1–1,1			26		
	5y – <18y		0–1,0					
	Eo% B-Eo% Eo B-Eo#	≥ 18y	M/F			0,4–6,0	%	17
		1y – <4y				<8,3		26
4y – <15y		<13						
15y – <18y		<6,7						
≥ 18y			0,02–0,4	10 ⁹ /L	17			
0d – <7d			0,2–0,7		5			
7d – <14d			0,2–0,8					
14d – <3m			0,2–0,6					
3m – <6m			0–1,1					
6m – <1y			0–1,0					
1y – <4y			<0,8	26				
4y – <15y			<1,0					
15y – <18y			<0,5					
Baso% B-Baso% Baso B-Baso#			≥18y	M/F	0,1–1,3	%	17	
	1y – <18y		<1,2		26			
	≥18y			0,01–0,08	10 ⁹ /L	17		
	0d – <7d			0–0,3		5		
	7d – <1y			0–0,2				
	1y – <18y	<0,1		26				
IG% B-IG%	≥18y	M/F	0-0,5	%	17			
	1y – <18y		<0,8		26			

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
IG B-IG#	≥18y		0–0,03	10 ⁹ /L	17
	1y – <18y		<0,05		26
NRBC% B-NRBC% NRBC# B- NRBC#	1y – <18y	M/N	<1,2	%	26
	1y – <18y		<0,12	10 ⁹ /L	
ERYTHROCYTE SEDIMENTATION RATE B-ESR					
Erythrocyte sedimentation rate B-ESR	17y – <51y	F	<13	mm/h	3
	51y – <61y		<20		
	61y – <70y		<21		
	≥70y		<36		
	17y – <51y	M	<11		
	51y – <61y		<13		
	61y – <70y		<15		
	≥70y		<31		
COAGULATION					
Prothrombin time P-PT%	All	M/F	>70	%	1
International normalized ratio INR	≥ 18y	M/F	0,80–1,20		1
	0d – <3d		1,15–1,35		9
	3d – <1m		1,05–1,35		
	1m – <1y		0,86–1,22		
	1y – <6y		0,92–1,14		
	6y – <11y		0,87–1,20		
	11y – <18y		0,97–1,30		
Activated partial thromboplastin time P-APTT	≥ 18y	M/F	28,9–38,1	sec	1
	0d – <3d		34,3–44,8		9
	3d – <1m		29,5–42,2		
	1m – <1y		35,1–46,3		
	1y – <6y		33,6–43,8		
	6y – <11y		31,8–43,7		
	11y – <18y		33,9–46,1		
Thrombin time P-TT	All	M/F	<21	sec	1
Fibrinogen P-Fibr	≥18y	M/F	2,0–4,0	g/L	1
	0d – <3d		1,92–3,74		9
	3d – <1m		2,83–4,01		
	1m – <1y		0,82–3,83		
	1y – <6y		1,62–4,01		
	6y – <11y		1,99–4,09		
	11y – <18y		2,12–4,33		
Factor VII	≥18y	M/F	55 –170	%	1

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
P-FVII	0d – <3d		52–88		9
	3d – <1m		67–107		
	1m – <1y		83–160		
	1y – <6y		72–150		
	6y – <11y		70–156		
	11y – <18y		69–200		
Factor VIII P-FVIII:C	≥ 18y	M/F	60–150	%	1
	0d – <3d		105–329		9
	3d – <1m		83–274		
	1m – <1y		54–145		
	1y – <6y		36–185		
	6y – <11y		52–182		
	11y – <18y		59–200		
Factor IX P-FIX	≥18y	M/F	60–150	%	1
	0d – <3d		35–56		9
	3d – <1m		44–97		
	1m – <1y		43–121		
	1y – <6y		44–127		
	6y – <11y		48–45		
	11y – <18y		64–216		
Factor XI P-FXI	≥18y	M/F	60–150	%	1
	0d – <3d		7–41		9
	3d – <1m		24–79		
	1m – <1y		62–125		
	1y – <6y		65–162		
	6y – <11y		65–162		
	11a – <18a		65–139		
Factor VIII inhibitor Factor IX inhibitor P-FVIII inh, P-FIX inh	All	M/F	Negative (<0,6)	BU	23
Factor inhibitor screening P-F inh screen	All	M/F	Negative		1
Von Willebrand factor P-vWF	≥18y	M/F	50–160	%	1
	0d – <3d		102–158		9
	3d – <1m		96–152		
	1m – <1y		53–116		
	1y – <6y		62–109		
	6y – <11y		74–111		
	11y – <18y		58–136		
Von Willebrand	All	M/F	48–173	%	24

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
factor activity P-vWF Act					
Von Willebrand factor activity ratio P-vWF Act/P-vWF	All	M/F	<0,6–0,7		25
Free Protein S P-fPS	≥18y	M	70–148	%	1
		F	50–134		1
	0d – <3d 3d – <1m 1m – <1y 1y – <6y 6y – <11y 11y – <18y	M/F	37–42		9
			40–57		
			80–116		
			63–120		
			83–123		
			76–127		
Protein C P-PC	≥ 18y	M/F	70–130	%	1
			0d – <3d		24–44
	3d – <1m		28–54		
	1m – <1y		31–112		
	1y – <6y		65–127		
	6y – <11y		71–129		
	11y – <18y		66–118		
	Activated protein C resistance P-APC-R		All		M/F
Antithrombin III P-AT III	≥ 18y	M/F	80–120	%	1
			0d – <3d		58–90
	3d – <1m		60–89		
	1m – <1y		72–134		
	1y – <6y		101–131		
	6y – <11y		95–134		
	11y – <18y		96–126		
	D-dimer P-D-Di		≥18y		M/F
0d – <3d		<2,47		9	
3d – <1m		<2,74			
1m – <1y		<0,42			
1y – <6y		<0,53			
6y – <11y		<0,56			
11y – <18y		<0,39			
Lupus sensitive APTT P-PTT-LA		All	M/F	Negative (35–48)	

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
Lupus anticoagulant (normalized ratio) P-LA normratio	All	M/F	Negative Normratio <1,2		1
Low molecular weight heparin P-LMWH Unfractionated heparin P-UFH	All	M/F	Missing in normal plasma without treatment (<0,1 kIU/L) Treatment with heparin – result depends on dosage, time of sampling	kIU/L	1
Rivaroxaban P-RXN	All	M/F	Missing in normal plasma without treatment (< 25 µg/L) Treatment with rivaroxaban – result depends on renal function, dosage, time of sampling	µg/L	1
Apixaban P-APBN	All	M/F	Missing in normal plasma without treatment (< 23 µg/L) Treatment with apixaban – result depends on renal function, dosage, time of sampling	µg/L	1
Edoxaban P-EDBN	All	M/F	Missing in normal plasma without treatment (< 20 µg/L) Treatment with edoxaban – result depends on renal function, dosage, time of sampling	µg/L	1
Dabigatran P-DBTN	All	M/F	Missing in normal plasma without treatment (< 15 µg/L)	µg/L	1

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
			Treatment with dabigatran – result depends on renal function, dosage, time of sampling		
Plasminogen P-Plasm	≥18a	M/F	80–120	%	1
Platelet function assay with collagene and epinephrine B-PFA-Col/Epi	All	M/F	82–150	sec	14
Platelet function assay with collagene and adenosine diphosphate B-PFA-Col/ADP	All	M/F	62–100	sec	14
Platelet function assay for detection of P2Y12 receptor blockade B-PFA-P2YP12	All	M/F	≤106	sec	11
CEREBROSPINAL FLUID ANALYSIS, CSF-Diff-a					
Leukocytes CSF-WBC	≥16y	M/F	<6	10 ⁶ /L	6 10
	≤28p		<20		
	29d – <3m		<10		
	3m – <16y		<6		
Erythrocytes CSF-RBC	≥18a		<6		
	Newborn, preterm ≤7d		<1000		
	Newborn, term ≤7d		<800		
	7d – ≤28d		<50		
	29d – <18y		<6		
CEREBROSPINAL FLUID MICROSCOPY, CSF-Diff-m					
Lymphocytes	≥18y	M/F	63–99	%	6
Monocytes			3–37		
Neutrophils			0–2		
Lymphocytes	Neonate (≤28d)		2–38		
Monocytes			50–94		
Neutrophils			0–8		
URINALYSIS DIPSTICK U-strip					

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
Specific gravity U-SG strip	≥18y	M/F	1,005–1,030		20
pH U-pH strip			5,0–8,0		19
Leukocytes U-WBC strip			Negative		21
Erythrocytes U-RBC strip			Negative		
Nitrite U-Nit strip			Negative		
Protein U-Prot strip			Negative		
Glucose U-Gluc strip			Negative		
Ketone U-Ket strip			Negative		
Urobilinogen U-Ubg strip			Negative		
Bilirubin U-Bil strip			Negative		
URINE FLOW CYTOMETRY U-Fc					
Erythrocytes U-RBC Fc	≥18a	M/N	Negative (<23)	10 ⁶ /L	22
Leukocytes U-WBC Fc			Negative (<25)		
Squamous epithelial cells U-SquaEC Fc			Negative (<31)		
Transitional epithelial cells U-TranEC Fc			Negative (<1)		
Tubular epithelial cells U-RTEC FC			Negative (<3)		
Hyaline casts U-HyCAST Fc			Negative (<1)		
Pathological casts U-PathCAST Fc			Negative (<1)		
Bacteria U-BACT Fc			Negative (<1200)		
Crystals U-XTAL Fc			Negative (<10)		
Yeast-like Cells U-YLC Fc			Negative (<1)		
URINE SEDIMENT MICROSCOPY U-Sed-m panel					
Erythrocytes	All	M/F	≤ 1	/hpf	18
Leukocytes		M	≤ 2		
		F	≤ 4		

Analyte Abbreviation	Age	Sex	Value	Unit	Reference
FECAL OCCULT BLOOD (St-Hb QN)					
National colon cancer screening	All	M/F	<20 (decision limit)	µg/g	15
In clinical indications			<15		16

References

1. Diagnostica Stago metoodilised juhendid
3. Dacie and Lewis, Practical Haematology, 2017
4. Nordic Reference Interval Project 2003
5. Calgary Laboratory Services, CBC Reference values 2016
6. CLSI H56-A (2006)
8. Wintrobe's Clinical Hematology, 2003
9. Diagnostica Stago 2016
10. Sihtasutus Tartu Ülikooli Kliinikum Lastekliinik Valvearsti teatmik 2019
11. Innovance PFA2Y kasutusjuhend, 2012
14. Dade PFA Collagen/EPI Test Cartidge and Dade PFA Collagen/ADP Test Cartidge kasutusjuhend, 2012
15. Jämesoolevähi sõeluuringu korraldusjuhend 1.0
16. Orion Diagnostica. QuikRead go iFOBT, assay procedure, v151053-3
17. Hematoloogilise automaatuuringu referentsväärtused Eesti täiskasvanutel, Eesti Arst 2020; 99(5):277-283
18. Heil, W., Ehrhardt, V. 2008. Reference Ranges for Adults and Children.
19. Brunzel, N. A. 2013. Fundamentals of Urine and Body Fluid Analysis. Third Edition. Elsevier.
20. Sysmex Meditape UC-10S testribade metoodiline juhend (v 05/2017)
21. Sysmex Meditape UC-9A testribade metoodiline juhend (v 06/2017)
22. Sysmex UF-4000 General Information tootja juhend (v 09/2018)
23. Miller CH. Laboratory testing for factor VIII and IX inhibitors in hemophilia: A review. Haemophilia. 2018 March; 24(2): 186–197
24. Siemens Innovanve VWF Ac metoodiline juhend (Rev. 02, 2011-03)
25. Paula D. James, Nathan T. Connell, Barbara Ameer, Jorge Di Paola, Jeroen Eikenboom, Nicolas Giraud, Sandra Haberichter, Vicki Jacobs-Pratt, Barbara Konkle, Claire McLintock, Simon McRae, Robert R. Montgomery, James S. O'Donnell, Nikole Scappe, Robert Sidonio, Veronica H. Flood, Nedaa Husainat, Mohamad A. Kalot, Reem A. Mustafa; ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. *Blood Adv* 2021; 5 (1): 280–300.
26. Bohn, M.K., Higgins, V., Tahmasebi, H., et al. Complex biological patterns of hematology parameters in childhood necessitating age- and sex-specific reference intervals for evidence-based clinical interpretation. *Int J Lab Hematol.* 2020; 42: 750– 760. <https://doi.org/10.1111/ijlh.13306>